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Abstract
The era of precision oncology is marked with prominent successes in the therapy of advanced soft tissue sarcomas,
breast cancer, ovarian cancer and haematological neoplasms, among others. Moreover, recent trials of immune
checkpoint inhibitors in melanoma, non-small cell lung carcinoma, and head and neck cancers have significantly
influenced the therapeutic landscape by providing promising evidence for immunotherapy efficacy in the adjuvant
setting in high-risk locoregional disease. To speed up the introduction of targeted therapy for cancer patients, novel
phase II trials are being designed, and may likely form the basis for the ‘landmark trials’ of the future. A special
article collection in BMC Medicine, “Spotlight on landmark oncology trials”, features articles from invited experts on
recent clinical practice-changing trials.
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Background
The era of precision medicine has led to significant devel-
opments in the therapy of advanced soft tissue sarcomas
(STS), breast cancer, ovarian cancer and haematological
neoplasms, among others. However, cancer research also
faces challenges in the effective development and assess-
ment of targeted therapeutics [1], including the need for
early evaluation of potential biomarkers by translational
and correlative studies.
In this editorial, we discuss the special article collec-
tion entitled “Spotlight on landmark oncology trials” re-
cently published in BMC Medicine, which focuses on
the core clinical trials of selected solid tumours (lung
cancer [2], melanoma [3, 4], STS [5], head and neck
cancer [6]). We also highlight selected and recent
practice-changing trials in chronic lymphocytic leu-
kaemia as well as breast and gynaecological cancers,
and review the advances offered by the development
of novel clinical trial designs.
Recent landmark immunotherapy trials – melanoma,
non-small cell lung carcinoma (NSCLC), head and
neck cancer
The first articles in the special article collection focus on
landmark clinical trials in selected advanced solid tumours,
with special attention on the most studied tumours with
regards to immunotherapy development, namely melanoma
[3, 4], NSCLC [2], and head and neck cancer [6]. Recent de-
velopments and approvals in immunotherapy have signifi-
cantly changed the landscape of melanoma and NSCLC
therapy in the metastatic setting, and open various possibil-
ities for adjuvant treatment in high-risk locoregional disease
[7–10]. In this article series, worldwide renowned experts in
their fields provided an extensive overview on the state of
the art in immunotherapy and discussed the possible future
paths in these, still difficult, types of malignancies.
The current results of anti-PD-1 therapy with pembro-
lizumab or nivolumab monotherapy in melanoma indi-
cated a median overall survival (OS) of approximately
2 years, but the combination of anti-PD-1 and anti-
CTLA-4 (nivolumab with ipilimumab) was shown to be
superior in terms of progression-free survival (PFS) and
OS (Table 1) [11–15]. Further clinical trials are under
way to determine how best to integrate combination im-
munotherapy and other treatment modalities as well as
to establish the correct sequence of therapy with tar-
geted treatment in BRAF-mutated cases.
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The team lead by Professor Jean-Charles Soria dis-
cussed the successes and failures of immunotherapy in
the first-line treatment of NSCLC [2]. Moreover, three
anti-PD-1/anti-PD-L1 agents, pembrolizumab, nivolu-
mab and atezolizumab, have been approved for second-
line therapy of NSCLC [16–18]; however, contrary to
melanoma, patient selection to therapy should be based
on PD-L1 expression level of tumour cells.
Recent landmark trials in STS
Another topic featured in this article collection is sys-
temic therapy in STS [5], which is a heterogeneous
group of rare solid tumours. Despite optimal local treat-
ment, approximately 50% of adult patients with localised
STS develop distant metastases and die of metastatic
disease. A limited number of drugs have shown activity
in advanced disease, and due to the rarity of these tu-
mours, clinical trials in sarcoma include many subtypes
and are mainly initiated by academic research groups.
Recent developments in the classification of STS, in-
sights into their molecular pathogenesis and the optimal
treatment strategies have evolved considerably during the
past decades and have led to the introduction of new ther-
apies. Nevertheless, the selection of systemic therapy must
be strictly individualised and based upon several factors,
including the histology and biological behaviour of the
disease. A summary of recent pivotal trials for systemic
therapy in advanced STS is presented in Table 2 [19–22].
Recent landmark trials in breast and
gynaecological cancers
Recent landmark trials in HER2-positive breast cancer in-
clude those using dual HER2-targeted therapy pertuzu-
mab and trastuzumab with docetaxel. In the neoadjuvant
setting, the NeoSphere trial demonstrated significantly im-
proved pathological complete response rates [23] and a
trend favouring improved PFS and OS at 5 years [24]. Re-
sults from the CLEOPATRA trial in the metastatic setting
of the same treatment have produced remarkable results
[25]; the same combination produced a 56.5-month me-
dian OS compared with 40.8 months achieved with trastu-
zumab and docetaxel alone, showing an increase of
15.7 months to OS in the pertuzumab group. These re-
sults clearly demonstrate the superiority of dual HER2-
directed therapy. In ER-positive, HER2-negative metastatic
disease, the landmark trial (PALOMA 3) uses the CDK 4/
6 inhibitor, palbociclib [26, 27]. Median PFS was 9.5 months
in the fulvestrant plus palbociclib group and 4.6 months in
the fulvestrant plus placebo group with a hazard ratio of
0.46, which was highly statistically significant. However,
translational research did not discover any predictive bio-
marker subgroups [27] for the palbociclib effect.
The landmark phase III trials in high-grade serous
ovarian cancer are testing PARP inhibitors as maintenance
therapy after response to platinum-based therapy in re-
lapsed disease. Study 19 [28, 29] used olaparib against
placebo and demonstrated a PFS of 11.2 months in
BRCA-mutated patients compared with 4.3 months for
wild-type patients (hazard ratio, 0.18; P < 0.0001). A more
recent niraparib study had similar results [30], where pa-
tients in the niraparib group had a significantly longer PFS
than the placebo group in all cohorts tested (21.0 vs.
5.5 months in the gBRCA cohort; 12.9 vs. 3.8 months in
the non-gBRCA cohort for patients who had tumours with
homologous recombination deficiency; and 9.3 vs.
3.9 months in the overall non-gBRCA cohort; P < 0.001).
Both trials demonstrated significant benefit for mainten-
ance PARP inhibitors in all subgroups of platinum-
sensitive relapsed high-grade serous ovarian cancer.
Recent landmark trial in chronic lymphocytic
leukaemia (CLL): upfront therapy with ibrutinib in
elderly with chronic lymphocytic leukaemia (The
RESONATE-2 Trial)
With the advent of novel oral agents that are well toler-
ated and highly efficacious, the therapeutic landscape of
CLL underwent radical changes [31]. In phase 3 trials,
ibrutinib, a first-in-class Bruton tyrosine kinase (BTK)
Table 1 Summary of major trials with immunotherapy in advanced cutaneous melanoma
Study N (% 1st line) ORR Median PFS 2-year OS rate
Pembrolizumab (10 mg/kg every 2 weeks)
KEYNOTE-006
Robert et al., 2015 [11]
Schachter et al., 2016 [12]
279 (65.6%) 33.7% 5.6 months 55.0%
Pembrolizumab (10 mg/kg every 3 weeks)
KEYNOTE-006 Robert et al., 2015 [11]
Schachter et al., 2016 [12]
277 (66.8%) 32.9% 4.1 months 55.0%
Nivolumab in BRAF-negative melanoma
Checkmate-066 Robert et al., 2015 [13]
210 (100%) 40.0% 5.4 months 57.7%
Ipilimumab + Nivolumab Checkmate-067
Larkin et al., 2015 [14]
Larkin et al., 2017 [15]
314 (100%) 58.9% 11.7 months 64.0%
ORR overall response rate; OS overall survival; PFS progression-free survival
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inhibitor, showed efficacy over traditional salvage thera-
peutic options in patients with relapsed or refractory CLL
[32]. The importance of BTK inhibitors in the first-line set-
ting has been recently investigated in the RESONATE-2
study [33], a head-to-head clinical trial in which outcomes
were shown to be superior for patients who received ibruti-
nib in comparison to patients treated with chlorambucil
single agent. Indeed, ibrutinib demonstrated a survival ad-
vantage over chlorambucil despite the study’s crossover de-
sign. The strength of the study also relies on the good
tolerance profile of ibrutinib, which allows it to be adminis-
tered continuously and provide indefinite disease suppres-
sion even in elderly or unfit CLL patients. However, a
potential setback is represented by the control arm since
chlorambucil is no longer regarded an adequate therapy in
CLL [26]. Combinations of chlorambucil with an anti-
CD2O monoclonal antibody, such as rituximab, ofatumu-
mab or obinutuzumab, are now the standard of care in pa-
tients unsuited to receive fludarabine, cyclophosphamide
and rituximab [34–36]. Further, a trial comparing ibrutinib
plus obinutuzumab versus chlorambucil plus obinutuzu-
mab finished recruiting, but results are not yet mature
(ClinicalTrials.gov Identifier: NCT02264574). Therefore, in
absence of data from this and similar trials, either thera-
peutic choice is adequate in the day-to-day practice.
In conclusion, the RESONATE-2 trial demonstrates that
ibrutinib is a new important player in the treatment of
elderly unfit patients and in those with high-risk disease.
A potential shortcoming with the upfront use of ibrutinib
includes cost and indefinite treatment course [37]. Finally,
biomarker and minimal residual disease assessment may
ultimately be useful to guide the targeted agent or regimen
of choice and the duration of treatment [38].
Novel trial designs and conclusions
The landmark oncology trials highlighted in the BMC
Medicine series “Spotlight on landmark oncology trials”
and this editorial are recent trials that have produced
practice-changing results for patients. These trials repre-
sent the end of the long process of translating scientific
innovation and drug discovery, through first-in-man
studies, followed by phase II trials and finally by rando-
mised phase III trials as required for licensing of new
treatments. Novel trial designs could potentially lead to
a different type of landmark trial that would accelerate
the process and allow cancer patients to access new
treatments faster. In the phase I setting, there is a press-
ing need to develop better trial methodologies for novel
combinations, often of a standard chemotherapy with a
novel targeted agent. Di Veroli et al. [39] published an
interesting software to provide information in terms of
synergy and/or antagonism between two compounds. In
addition, adaptive designs for phase I combinations are
being developed [40].
In the era of precision cancer medicine, innovative
trial designs will also require the matching of novel
drugs with putative targets. Indeed, BATTLE, a land-
mark phase II trial using an adaptive randomised design,
tested four novel drugs and biomarker pairings in
NSCLC [41]. This was followed by BATTLE-2 [42], test-
ing combination treatments in the same disease. In neo-
adjuvant breast cancer, the I-SPY 1 and 2 trials have
successfully matched treatment and biomarkers, using
adaptive randomised designs [43, 44]. Landmark results
include those in triple negative breast cancer for the
combination of velaparib and carboplatin [44] and nera-
tinib in HER2-positive breast cancer [45]. The FOCUS 4
trial in metastatic colorectal cancer uses group-
sequential multi-arm, multi-stage methodology [46] to
achieve similar matching of novel therapy and biomarker
groups. Our own group is developing a novel Bayesian,
adaptive randomised methodology [47]. These designs
would allow recruitment of biomarker-negative patients,
often not included in other trials, and have the potential
for ‘perpetual’ designs, in which successful matching of
novel drugs and biomarkers would result in ‘graduation’
Table 2 Summary of recent pivotal clinical trials in advanced soft tissue sarcomas
Tumour type, phase
[reference]
Line of therapy Arms (experimental vs. control) Response rate Clinical benefit
rate
Median PFS
(months, P value)
Median OS
(months, P value)
Non-adipocytic soft
tissue sarcoma,
phase 3, n = 369 [19]
Second or later
(after anthracycline)
Pazopanib 800 mg/m2
vs. placebo
6% vs. 0% 73% vs. 38% 4.6 vs. 1.6
(P < 0.0001)
12.5 vs. 10.7
(P = 0.25)
Liposarcoma and
leiomyosarcoma,
phase 3, n = 518 [20]
Second or later
(after anthracycline)
Trabectedine 1.5 mg/m2
vs. dacarbazine 1000 mg/m2
10% vs. 7% 61% vs. 42% 4.2 vs. 1.5
(P < 0.001)
12.4 vs. 12.9
(P = 0.37)
Liposarcoma and
leiomyosarcoma,
phase 3, n = 452 [21]
Third or later
(after anthracycline)
Eribulin mesylate 1.4 mg/m2 vs.
dacarbazine 850–1200 mg/m2
5% vs. 4% 57% vs. 52% 2.6 vs. 2.6
(P = 0.23)
13.5 vs. 11.5
(P = 0.01)
Soft tissue sarcoma,
phase 2, n = 133 [22]
First line Olaratumab 15 mg/kg plus
doxorubicin 75 mg/m2 vs.
doxorubicin alone 75 mg/m2
18.2% vs. 11.9% 77.3% vs. 62.7% 6.6 vs. 4.1
(P = 0.06)
26.5 vs. 14.7
(P = 0.0003)
OS overall survival; PFS progression-free survival
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of the pair to a phase III trial, along with the rapid rejec-
tion of novel drugs that did not work. More effective
and cost-efficient phase II trial designs would rapidly
lead to landmark trials and practice-changing results.
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